PsyRING - Psychiatric Research Institute of Neuroscience in Glasgow
Unique translational solutions for drug discovery and development in Psychiatric disease
PsyRING provides an integrated portfolio of services and collaborative opportunities incorporating a strong clinical component to companies active in the research and development of drugs for psychiatric disease.
PsyRING offers a range of high quality models and tools for target identification, target validation and compound testing in preclinical and clinical settings. PsyRING is an excellent colloborative partner to initiate or expand discovery programmes.
Drawing upon skills of its founding institutions, the University of Glasgow, the University of Strathclyde, and Gartnavel Royal Hospital, Glasgow, PsyRING provides access to cutting edge technologies, valuable source materials, clinical resources and novel ideas to provide support throughout the development process.
PsyRING staff review thalamic dysfunction in schizophrenia.
In this review the PsyRING staff provide a new perspective on the role of thalamic dysfunction in schizophrenia.
Pratt, J.A. and Morris, B.J. (2015) The thalamic reticular nucleus: a functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery. Journal of Psychopharmacology, 29, 127-137
PsyRING staff review preclinical models of aspects of schizophrenia.
In this critical review the PsyRING staff address the extent to which preclinical models can reproduce key features of schizophrenia. The review synthesises current understanding and proposes a framework for future progress.
Pratt, J.A., Winchester, C.L., Dawson, N, and Morris, B.J. (2012) Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nature Reviews Drug Discovery, 22, 560-79